4.3600
23-5月-25 13:45:00
15 分の遅延
株式
-0.0200
-0.46%
本日の幅
4.2400 - 4.4000
ISIN
N/A
ソース
NASDAQ
Verve Therapeutics Reports Preclinical Data Demonstrating Potent Editing of ANGPTL3 Gene Using Proprietary GalNAc-LNP Delivery Technology in Non-Human Primates
09 11 2021 03:30:00 提供 Nasdaq GlobeNewswire
Verve Therapeutics to Participate in the Jefferies Gene Therapy/Editing Summit
21 10 2021 03:30:00 提供 Nasdaq GlobeNewswire